O&M Movianto to ship and warehouse DuraGraft® Endothelial Damage Inhibitor to countries where product is cleared for sale.
Jupiter, FL (January 6, 2016) – Somahlution, a global biotechnology company focused on advancing the science of organ and surgical conduit transplantation, has announced that it has signed an agreement with Owens & Minor’s Movianto Group (O&M Movianto) to house and ship DuraGraft, globally. DuraGraft received its CE mark in August of 2014, and has continued to attain marketing approvals in countries located in the Asia-Pacific and Middle East regions.
Somahlution will use Movianto’s logistics facility located in Oss, Netherlands, a state-of-the art facility specializing in medical devices, pharmaceuticals, and biotech products. It is ISO 9001:2008 and ISO 13485 certified. The Oss facility is one of O&M Movianto’s 21 logistics centers strategically located in 11 countries across Europe. Owens & Minor is a leading healthcare logistics company dedicated to Connecting the World of Medical Products to the Point of CareSM by providing vital supply chain services to healthcare providers and manufacturers.
“We are pleased to have such a viable and efficient partner in the transportation and storage of our products,” said Satish Chandran, Ph.D., and Somahlution Chief Executive Officer.
“We are dedicated to being the preferred European healthcare logistics partner for companies like Somahlution,” said Charles C. Colpo, Senior Vice President of Strategic Relationships and head of O&M’s operations in Europe. “Our mission is connecting the world of medical products, including vital life science products, to the point-of-care, where our services can enable better patient outcomes. We have the facilities, network and knowledge to provide exceptional service to our clients.”
Somahlution is a global leader in the development and commercialization of innovative, high value-added solutions to advance clinical performance, define standard of care and improve patient outcomes. Using patented and proprietary technologies, Somahlution is dedicated to providing medical products focused on Ischemia Reperfusion Injury (IRI) to improve healthcare delivery to patients around the world. The company’s flagship product, DuraGraft is the first Endothelial Damage Inhibitor (EDI) developed to prevent vein graft failure, which may be associated with vein graft disease. For more information about the company, please visit www.somahlution.com.
About Owens & Minor, Inc.
Owens & Minor, Inc. (NYSE: OMI) is a leading healthcare logistics company dedicated to Connecting the World of Medical Products to the Point of CareSM by providing vital supply chain services to healthcare providers and manufacturers of healthcare products. Owens & Minor provides logistics services across the spectrum of medical products from disposable medical supplies to devices and implants. With logistics platforms strategically located in the United States and in Europe, Owens & Minor serves markets where three quarters of global healthcare spending occurs. Owens & Minor’s customers span the healthcare market from independent hospitals to large integrated healthcare networks, as well as group purchasing organizations, healthcare products manufacturers, and the federal government. A FORTUNE 500 company, Owens & Minor is headquartered in Richmond, Virginia, and has annualized revenues exceeding $9 billion. For more information about Owens & Minor, visit the company website at www.owens-minor.com.
- # # # -
Back to the latest news